ADMA Biologics, Inc. (ADMA) shareholders
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3036% below fair value
$13.68+0.44 (+3.32%)
Close on Nov 13, 2026Market cap $3.06BP/E 17.8Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.8%
206M of 224M shares
Institutional holders
323
52 new, 83 sold out
Net institutional buying
-6M
In Q2 2026
Insider trades, 12 months
5 buys · 11 sales
Net sold $2.86M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 35,907,601 | 15.10% | 13G (passive) amendment | Mar 31, 2025 |
| State Street Corporation | 13,675,348 | 6.10% | 13G (passive) | Sep 30, 2026 |
| Vanguard Capital Management | 12,110,153 | 5.08% | 13G (passive) | Mar 31, 2026 |
| Invesco Ltd. | 11,785,202 | 5.00% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ADMA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 38,355,684 | 17.12% | $321.04M | +1,524,910 | 0.00% |
| State Street Corp | 17,116,022 | 7.64% | $143.26M | +3,031,817 | 0.00% |
| Vanguard Capital Management LLC | 10,103,809 | 4.51% | $84.57M | −203,062 | 0.00% |
| Vanguard Portfolio Management LLC | 10,088,490 | 4.50% | $84.44M | +1,219,833 | 0.00% |
| Rubric Capital Management LP | 9,339,414 | 4.17% | $78.17M | +7,530,006 | 0.72% |
| Capital Research Global Investors | 8,756,374 | 3.91% | $73.29M | −2,434,742 | 0.01% |
| First Trust Advisors LP | 7,798,351 | 3.48% | $65.27M | +7,438,134 | 0.04% |
| Geode Capital Management, LLC | 6,059,984 | 2.71% | $50.73M | +235,868 | 0.00% |
| Caligan Partners LP | 5,725,007 | 2.56% | $47.92M | +968,496 | 2.25% |
| D. E. Shaw & Co., Inc. | 5,274,597 | 2.35% | $44.15M | +4,713,770 | 0.02% |
| Nantahala Capital Management, LLC | 4,719,986 | 2.11% | $39.51M | New | 0.66% |
| Dimensional Fund Advisors LP | 3,606,208 | 1.61% | $30.18M | −1,399,273 | 0.01% |
| Goldman Sachs Group Inc | 3,513,583 | 1.57% | $29.41M | +710,053 | 0.00% |
| B Group, Inc. | 3,262,542 | 1.46% | $27.31M | +55,000 | 12.82% |
| Nuveen, LLC | 3,260,349 | 1.46% | $27.29M | −2,837,876 | 0.01% |
| Duquesne Family Office LLC | 2,784,110 | 1.24% | $23.30M | +1,238,500 | 0.45% |
| Northern Trust Corp | 2,415,971 | 1.08% | $20.22M | +138,659 | 0.00% |
| Morgan Stanley | 2,265,443 | 1.01% | $18.96M | −168,936 | 0.00% |
| Ranger Investment Management, L.P. | 2,115,417 | 0.94% | $17.71M | −168,393 | 1.12% |
| Charles Schwab Investment Management Inc | 2,092,594 | 0.93% | $17.52M | −3,178 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 323 | 206M | 91.8% | 52 / 90 | 148 / 83 | 45M | 52M |
| Q1 2026 | 357 | 212M | 94.6% | 70 / 136 | 109 / 61 | 71M | 58M |
| Q4 2025 | 356 | 220M | 98.4% | 59 / 140 | 119 / 61 | 31M | 30M |
| Q3 2025 | 365 | 220M | 98.1% | 65 / 97 | 161 / 64 | 39M | 31M |
| Q2 2025 | 368 | 212M | 94.5% | 79 / 152 | 107 / 55 | 28M | 24M |
| Q1 2025 | 347 | 207M | 92.5% | 68 / 128 | 112 / 37 | 28M | 20M |
| Q4 2024 | 321 | 204M | 91.2% | 76 / 124 | 104 / 57 | 27M | 30M |
| Q3 2024 | 306 | 209M | 93.3% | 94 / 102 | 95 / 39 | 74M | 28M |
| Q2 2024 | 252 | 181M | 81.0% | 59 / 87 | 85 / 18 | 31M | 32M |
| Q1 2024 | 214 | 183M | 81.7% | 51 / 86 | 53 / 19 | 32M | 22M |
| Q4 2023 | 184 | 173M | 77.3% | 21 / 72 | 58 / 25 | 19M | 17M |
| Q3 2023 | 188 | 171M | 76.4% | 25 / 89 | 46 / 15 | 19M | 13M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
293 funds held ADMA in Q2 2026, 64% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ADMA | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 13,966,706 | 6.24% | $116.90M | 0.11% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 8,524,390 | 3.81% | $71.35M | 0.08% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 7,823,567 | 3.49% | $65.48M | 2.33% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,793,162 | 3.48% | $65.23M | 0.61% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 7,023,200 | 3.14% | $58.78M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,991,537 | 2.67% | $50.15M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,660,292 | 1.19% | $22.27M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,522,472 | 1.13% | $21.11M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,521,484 | 1.13% | $21.33M | 0.06% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 2,131,117 | 0.95% | $17.84M | 0.11% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 2,129,592 | 0.95% | $17.82M | 0.12% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 2,082,705 | 0.93% | $17.43M | 0.21% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,598,768 | 0.71% | $13.38M | 0.15% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 1,565,647 | 0.70% | $13.10M | 0.11% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,448,225 | 0.65% | $12.12M | 0.03% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adam S. Grossman | President and CEO, Director | 2,651,734 | 1.18% | Nov 5, 2026 |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | 443,061 | 0.20% | Jul 28, 2026 |
| Terry Kohler | CFO and Treasurer | 143,149 | 0.06% | Jul 17, 2026 |
| Brad L. Tade | CFO and Treasurer | 232,940 | 0.10% | Feb 23, 2026 |
| Jerrold B. Grossman | Director | 543,141 | 0.24% | May 28, 2026 |
| Lawrence P. Guiheen | Director | 186,510 | 0.08% | Mar 17, 2026 |
| Steve Elms | Director | 2,143,750 | 0.96% | Mar 9, 2026 |
| Young Kwon | Director | 263,020 | 0.12% | Feb 11, 2026 |
| Alison Cecily Finger | Director | 45,619 | 0.02% | Feb 11, 2026 |
| Eduardo Rene Salas | Director | 21,579 | 0.01% | Feb 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Adam S. Grossman President and CEO, Director | Nov 5, 2026 | Sale(10b5-1 plan) | −42,000 | $12.00 | $504.00K | 2,070,777 |
| Adam S. Grossman President and CEO, Director | Nov 5, 2026 | Sale(10b5-1 plan) | −105,000 | $12.00 | $1.26M | 2,112,777 |
| Adam S. Grossman President and CEO, Director | Nov 5, 2026 | Option exercise | +105,000 | $5.40 | $567.00K | 2,217,777 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Jul 24, 2026 | Tax withholding | −3,177 | $8.37 | $26.59K | 443,061 |
| Terry Kohler CFO and Treasurer | Jul 16, 2026 | Award | +85,130 | – | – | 143,149 |
| Jerrold B. Grossman Director | May 27, 2026 | Buy | +6,400 | $7.91 | $50.62K | 520,284 |
| Jerrold B. Grossman Director | May 12, 2026 | Buy | +12,500 | $8.01 | $100.13K | 513,884 |
| Jerrold B. Grossman Director | May 11, 2026 | Buy | +12,500 | $8.01 | $100.13K | 501,384 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Apr 1, 2026 | Tax withholding | −20,362 | $9.11 | $185.50K | 446,238 |
| Lawrence P. Guiheen Director | Mar 17, 2026 | Gift | −30,000 | – | – | 105,520 |
| Lawrence P. Guiheen Director | Mar 17, 2026 | Gift | +30,000 | – | – | 30,000 |
| Adam S. Grossman President and CEO, Director | Mar 16, 2026 | Sale(10b5-1 plan) | −15,000 | $15.16 | $227.40K | 2,118,777 |
| Adam S. Grossman President and CEO, Director | Mar 16, 2026 | Sale(10b5-1 plan) | −6,000 | $15.16 | $90.96K | 2,112,777 |
| Adam S. Grossman President and CEO, Director | Mar 16, 2026 | Option exercise | +15,000 | $5.40 | $81.00K | 2,133,777 |
| Lawrence P. Guiheen Director | Mar 13, 2026 | Option exercise | +30,000 | $3.66 | $109.80K | 135,520 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 9, 2026 | Option exercise | +1,525 | $2.35 | $3.58K | 474,521 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 9, 2026 | Option exercise | +2,175 | $1.55 | $3.37K | 476,696 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 9, 2026 | Sale | −10,096 | $15.63 | $157.80K | 466,600 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 9, 2026 | Option exercise | +2,646 | $2.83 | $7.49K | 472,996 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 9, 2026 | Option exercise | +1,250 | $4.31 | $5.39K | 470,350 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 9, 2026 | Option exercise | +2,500 | $5.00 | $12.50K | 469,100 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 9, 2026 | Other | −91,266 | – | – | 466,600 |
| Adam S. Grossman President and CEO, Director | Mar 7, 2026 | Tax withholding | −29,513 | $15.39 | $454.21K | 2,118,777 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 7, 2026 | Tax withholding | −4,235 | $15.39 | $65.18K | 557,866 |
| Adam S. Grossman President and CEO, Director | Mar 6, 2026 | Tax withholding | −56,438 | $15.39 | $868.58K | 2,148,290 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Mar 6, 2026 | Tax withholding | −10,059 | $15.39 | $154.81K | 562,101 |
| Steve Elms Director | Mar 6, 2026 | Buy | +7,000 | $15.39 | $107.73K | 2,045,730 |
| Steve Elms Director | Mar 5, 2026 | Buy | +7,000 | $15.67 | $109.69K | 2,038,730 |
| Adam S. Grossman President and CEO, Director | Feb 26, 2026 | Tax withholding | −54,858 | $15.18 | $832.74K | 2,204,728 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Feb 19, 2026 | Tax withholding | −8,161 | $16.32 | $133.19K | 572,160 |
| Adam S. Grossman President and CEO, Director | Feb 19, 2026 | Tax withholding | −24,793 | $16.32 | $404.62K | 2,259,586 |
| Brad L. Tade CFO and Treasurer | Feb 19, 2026 | Tax withholding | −6,479 | $16.32 | $105.74K | 232,940 |
| Adam S. Grossman President and CEO, Director | Feb 17, 2026 | Option exercise | +15,000 | $5.40 | $81.00K | 2,305,379 |
| Adam S. Grossman President and CEO, Director | Feb 17, 2026 | Sale(10b5-1 plan) | −15,000 | $16.08 | $241.20K | 2,290,379 |
| Adam S. Grossman President and CEO, Director | Feb 17, 2026 | Sale(10b5-1 plan) | −6,000 | $16.08 | $96.48K | 2,284,379 |
| Eduardo Rene Salas Director | Feb 9, 2026 | Award | +10,690 | – | – | 21,579 |
| Alison Cecily Finger Director | Feb 9, 2026 | Award | +10,690 | – | – | 45,619 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Feb 9, 2026 | Award | +91,631 | – | – | 580,321 |
| Jerrold B. Grossman Director | Feb 9, 2026 | Award | +10,690 | – | – | 488,884 |
| Adam S. Grossman President and CEO, Director | Feb 9, 2026 | Award | +282,529 | – | – | 2,290,379 |
| Steve Elms Director | Feb 9, 2026 | Award | +10,690 | – | – | 98,020 |
| Young Kwon Director | Feb 9, 2026 | Award | +10,690 | – | – | 263,020 |
| Lawrence P. Guiheen Director | Feb 9, 2026 | Award | +10,690 | – | – | 105,520 |
| Adam S. Grossman President and CEO, Director | Dec 15, 2025 | Sale(10b5-1 plan) | −15,000 | $19.79 | $296.85K | 2,013,850 |
| Adam S. Grossman President and CEO, Director | Dec 15, 2025 | Option exercise | +15,000 | $5.40 | $81.00K | 2,028,850 |
| Adam S. Grossman President and CEO, Director | Dec 15, 2025 | Sale(10b5-1 plan) | −6,000 | $19.79 | $118.74K | 2,007,850 |
| Adam S. Grossman President and CEO, Director | Nov 19, 2025 | Sale(10b5-1 plan) | −15,000 | $16.00 | $240.00K | 2,019,850 |
| Adam S. Grossman President and CEO, Director | Nov 19, 2025 | Option exercise | +15,000 | $5.40 | $81.00K | 2,034,850 |
| Adam S. Grossman President and CEO, Director | Nov 19, 2025 | Sale(10b5-1 plan) | −6,000 | $16.00 | $96.00K | 2,013,850 |
| Adam S. Grossman President and CEO, Director | Oct 24, 2025 | Option exercise | +15,000 | $5.40 | $81.00K | 2,040,850 |
| Adam S. Grossman President and CEO, Director | Oct 24, 2025 | Sale(10b5-1 plan) | −6,000 | $16.00 | $96.00K | 2,019,850 |
| Adam S. Grossman President and CEO, Director | Oct 24, 2025 | Sale(10b5-1 plan) | −15,000 | $16.00 | $240.00K | 2,025,850 |
| Adam S. Grossman President and CEO, Director | Sep 15, 2025 | Sale(10b5-1 plan) | −6,000 | $16.13 | $96.78K | 2,025,850 |
| Adam S. Grossman President and CEO, Director | Sep 15, 2025 | Sale(10b5-1 plan) | −15,000 | $16.13 | $241.95K | 2,031,850 |
| Adam S. Grossman President and CEO, Director | Sep 15, 2025 | Option exercise | +15,000 | $5.40 | $81.00K | 2,046,850 |
| Adam S. Grossman President and CEO, Director | Aug 15, 2025 | Sale(10b5-1 plan) | −6,000 | $16.88 | $101.28K | 2,031,850 |
| Adam S. Grossman President and CEO, Director | Aug 15, 2025 | Sale(10b5-1 plan) | −15,000 | $16.88 | $253.20K | 2,037,850 |
| Adam S. Grossman President and CEO, Director | Aug 15, 2025 | Option exercise | +15,000 | $5.40 | $81.00K | 2,052,850 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Jul 30, 2025 | Tax withholding | −1,208 | $18.59 | $22.46K | 488,690 |
| Kaitlin M. Kestenberg-Messina COO and SVP, Compliance | Jul 30, 2025 | Option exercise | +2,500 | $8.98 | $22.45K | 489,898 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
8.30%
18M shares short
Days to cover
7.1
At 3M shares a day
Change since last report
-7.6%
From 20M shares
Short volume, 20 days
48.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ADMA Biologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,423 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Adam S. Grossman Director, Officer | Nov 5, 2026 | 189,000 | $1.98M | Nov 5, 2026 | Vesting and settlement of restricted stock units granted on March 7, 2022. |
| Brad L. Tade Former Officer | Mar 10, 2026 | 50,026 | $790.91K | Mar 10, 2026 | Restricted Stock Units vesting - granted June 26, 2023 |
| Kaitlin M. Kestenberg-Messina Officer | Mar 9, 2026 | 10,096 | $155.38K | Mar 9, 2026 | Stock Option Exercise - Options Granted February 14, 2017 |
| Adam S. Grossman Director, Officer | Feb 17, 2026 | 209,000 | $3.36M | Feb 17, 2026 | Stock Option Exercise - Options Granted February 26, 2024 |
| Adam S. Grossman Director and Officer | Oct 24, 2025 | 63,000 | $960.75K | Oct 24, 2025 | Stock Option Exercise - Options |
| Adam S. Grossman Director and Officer | Jul 15, 2025 | 63,000 | $1.18M | Jul 15, 2025 | Stock Option Exercise - Options Granted February 26, 2024 |
| Steve Elms Director | Jun 12, 2025 | 425,621 | $9.31M | Jun 12, 2025 | Restricted Stock Units vested |
| Jerrold B. Grossman Director | Jun 9, 2025 | 10,000 | $206.10K | Jun 9, 2025 | Stock Option Exercise - Options Granted February 14, 2017 |
| Lawrence P Guiheen Rev Tr DTD 09/20/19 Director | Jun 4, 2025 | 20,000 | $415.00K | Jun 4, 2025 | OPTIONS EXERCISED |
| Lawrence P. Guiheen Director | May 21, 2025 | 29,000 | $572.76K | May 21, 2025 | Stock Option Exercise - Options granted 1/28/2016 |
| Adam S. Grossman Director and Officer | Mar 19, 2025 | 84,000 | $1.57M | Mar 19, 2025 | Restricted Stock Units Vesting |
| Adam S. Grossman Director and Officer | Nov 22, 2024 | 48,967 | $1.04M | Nov 22, 2024 | Restricted Stock Unit Vest |
| Brad L. Tade Officer | Nov 22, 2024 | 15,000 | $319.50K | Nov 22, 2024 | Restricted Stock Unit Vest |
| Lawrence P. Guiheen Director | Sep 9, 2024 | 9,000 | $146.34K | Sep 9, 2024 | Stock Options |
| Kaitlin M. Kestenberg-Messina Officer | Aug 30, 2024 | 24,150 | $415.86K | Aug 30, 2024 | Stock Options |
See a number that looks wrong?